Due to the findings of the aforementioned studies, the addition of zolbetuximab to chemotherapy in patients with CLDN18.2-positive/HER2-negative metastatic recurrent GC has become an established novel therapy in the first-line setting. Here, CLDN18 is linked to gastric cancer.